



January 1, 2022

Dear Patient:

My name is Steve Morris, I am the Chief Medical Officer of Biomea Fusion, and a board-certified internist and medical oncologist with over 30 years of academic research experience working at the Yale University School of Medicine and the St. Jude Children's Hospital, where I have conducted basic translational research and treated patients with menin-driven leukemias.

Thank you for considering to participate in our clinical study.

Biomea was founded with the goal to help patients like yourself safely and effectively beat their cancers. Our mission is to cure this disease. We understand that this is a tall goal, but we are dedicated in achieving it.

At Biomea we are using a very targeted approach to address directly a very crucial protein in your body which we found to be central to the growth and survival of your cancer - menin. We use sophisticated chemistry to inhibit this oncogenic pathway selectively and effectively. Our innovative medicine is called BMF-219, it irreversibly attaches to menin and inhibits its function. We believe that this approach may halt the cancer growth and over time may potentially provide a functional cure for this disease. The profile of BMF-219 is compelling as it exerts strong control over menin while maintaining what we believe will be a favorable safety profile.

We are all very hopeful to explore the clinical potential of this first-in-class and first-in-human irreversible menin inhibitor. Please be assured that we exist to serve you and will gladly welcome you to our clinical study.

Steve

Steve Morris | Chief Medical Officer



Biomea Fusion Inc
900 Middlefield Road, 4th Floor
Redwood City, CA 94063
www.biomeafusion.com